European Journal of Clinical and Experimental Medicine T.21, z. 4 (2023)

URI dla tej Kolekcjihttps://repozytorium.ur.edu.pl/handle/item/9493

Przeglądaj

Przeglądanie European Journal of Clinical and Experimental Medicine T.21, z. 4 (2023) według Temat "AIDS"

Wpisz kilka pierwszych liter i kliknij przycisk Przeglądaj
Aktualnie wyświetlane 1 - 2 z 2
  • Obrazek miniatury
    Pozycja
    Exploring the versatility of ciclopirox – from anti-fungal to anticancer agent and beyond
    (Publishing Office of the University of Rzeszow, 2023-12) Singh, Dhishank; Kaur, Ginpreet; Chintamaneni, Meena; Joshi, Hemant; Ramniwas, Seema; Tuli, Hardeep Singh
    Introduction and aim. Ciclopirox has been treating fungal infections for decades. Recent studies suggest ciclopirox may be repurposed to treat cancer, viral infections, and neurological disorders. Ciclopirox exerts anticancer by inhibiting multiple pathways of cancer cell growth and survival and anti-viral actions by reducing viral replication and altering the host immunological response to viral infection. Recent research suggests that ciclopirox may protect against neurodegenerative illnesses including Alzheimer’s and Parkinson’s. This narrative review shows ciclopirox’s potential to treat cancer, viral infections, and neurological diseases. Material and methods. Current relevant research publications focused on ciclopirox and its repurposing medicinal potential, therefore a well-designed technique was used to find them. „Ciclopirox”, „Anti-fungal”, „Anti-cancer”, „Repurposing”, and „Therapeutic potential” were used to search PubMed, Web of Science, EMBASE, and Google Scholar. Analysis of literature. Ciclopirox may reduce oxidative stress and inflammation, which may cause several illnesses. Overall, the repurposing of ciclopirox for the treatment of cancer, viral infections, and neurodegenerative disorders represents a promising avenue of research that warrants further investigation. Conclusion. It was concluded that CPX and olamine derivatives as outstanding antifungal medications, as well as provide information on ongoing research to use them for other illnesses.
  • Obrazek miniatury
    Pozycja
    Hematopoietic stem cell transplantation in the treatment of HIV infection – comparison of “Berlin patient”, “London patient” and “Dusseldorf patient”
    (Publishing Office of the University of Rzeszow, 2023-12) Brzyska, Anna; Bogucka, Julia; Bojarska, Małgorzata Kinga; Domańska, Natalia Anna; Piecewicz-Szczęsna, Halina
    Introduction and aim. Human Immunodeficiency Virus-1 (HIV-1) remains one of the major issues in global public health. The standard therapy for HIV-1 positive patients includes using antiretroviral therapy (ART). These medications ensure suppression of viral replication but do not lead to a cure for the patient. The aim of this study was to present hematopoietic stem cell transplantation (HSCT) as a malignant treatment method which led to cure for three HIV-1 positive patients. Material and methods. Literature available in April 2023 was searched by using the PubMed and Google Scholar databases. Articles were selected using the following words: HIV, AIDS, HSCT therapy, ART therapy. Analysis of the literature. In each case of these described HSCT, the donor of hematopoietic stem cells had a homozygous mutation in the HIV co-receptor CCR5 (CCR5Δ32/Δ32). This mutation leads to a permanent lack of the protein and prevents penetration of virus by using this receptor. After transplantation, all of these 3 patients remained virus-free despite discontinuation of ART therapy. Conclusion. More research is needed to reduce the risk of using HSCT and perhaps in the future be able to use this therapy in all HIV-infected people.